Germany's Uhlmann says that a process offered by its new range of
blister packaging machines that removes the need for an additional
product chain in the cartoner will help drugmakers save time, space
and money.
India's GVK BIO has secured a new research agreement with drug
giant Wyeth Pharmaceuticals, as more and more pharma firms are
relying on outside partners for drug discovery innovations.
Pharmaceutical manufacturers are now withdrawing from manufacturing
at an unprecedented rate, with four of the top 10 players
announcing major new outsourcing programmes in 2007, says IMS in a
new document which explores the implications...
IMS has identified 10 critical developments in 2007 that could have
a fundamental effect on the operating environment for
pharmaceutical companies in the coming years.
IT infrastructure and business process services firm Cognizant has
announced an alliance with CTC Laboratory Systems that aims to
assist Japanese pharmaceutical firms in enhancing efficiencies in
drug discovery and development.
Three Indian contract research organisations (CROs) - Asian
Clinical Trials (ACT), Veeda Clinical Research and Siro Clinpharm
have made recent global moves in order to add more muscle to their
industry presence.
At present India appears to be beating China in the race for Asia's
top clinical spot, according to new figures published by india´s
Planning Commission.
The use of disposable manufacturing equipment in pharmaceutical
production and greater need for containment equipment were
recurring themes at the Interphex show in Philadelphia last week,
and both were addressed by new equipment...
Quintiles has forged a new partnership that will allow it to begin
providing central laboratory services in Japan, where the clinical
research organisation (CRO) industry is gaining momentum.
The pharmaceutical industry has lost confidence in the UK as a
place to do business to an "alarming degree" and the
situation is only set to deteriorate, reveals new research.
inVentiv Clinical has become the latest contract research
organisation (CRO) to open up shop in blossoming Latin America in a
bid to gain more of a global reach.
Cognizant is gaining ground in the life sciences arena, this week
inking a $95m data management deal with AstraZeneca, just three
months after sealing another multi-million dollar deal with Merck
& Co.
Jubilant Organosys, India's largest custom research and
manufacturing services (CRAMS) provider, has scored new contracts
to the tune of $92m for the year thus far as its business continues
to gather momentum.
Europe's Novasecta has formed an alliance with Chinese contract
research organisations (CROs) Sundia Meditech and HD BioSciences to
provide their R&D services to European mid-sized biopharma
firms.
With increasing pressures on pharma pipelines leading to greater
interest in compound licensing, firms can be caught out by failing
to give scalability issues due attention, according to Joseph
D'Antuono speaking at last week's...
Vapourtec has made two new additions to its Flow Chemistry platform
available as the company make headway in an emerging field, which
aims to speed up laboratory processes in drug discovery.
Sanofi-Aventis has decided to pull out of its skin cancer
collaboration with IDM Pharma, leaving the Californian biopharma
firm considering job cuts as a way to lower costs.
Eisai is planning to step up its clinical research presence in Asia
and has chosen Singapore as a hub from which to coordinate its
research activities.
AstraZeneca's axe has made its latest appearance in South Africa,
with the sale of a packaging plant and the formation of an
outsourcing deal with its new owners.
With IMS Health's annual forecast for the pharma industry
predicting slower approvals, more black box warnings and the
continuation of the 'wave of genericization,' the shift by
pharma firms to refocus and reinvent...
Swiss pharma Novartis today announced the largest manufacturing investment in its history, revealing plans for a $700m (€486.5m) biotech facility to be built alongside its new solid dose plant in the low cost, high quality biopharma hub of Singapore.
The US Food and Drug Administration (FDA) has slammed
Sanofi-Aventis over its failure to act on known instances of fraud
during clinical trials of its antibiotic Ketek (telithromycin) -
accusations that the firm continues to deny.
Rumours that Pfizer is looking into buying a large stake in
Sanofi-Aventis, which could be seen as a prelude to a full takeover
bid, has prompted a flurry of shareholder activity.
Three of the world's biggest pharmaceutical companies have signed a
landmark deal with the UK government that will see them use stem
cell technology to road-test the safety of new compounds.
Californian marketing company BlueLithium has launched a new
web-based solution to help pharma companies overcome the challenges
of recruiting patients for clinical trials.
Pfizer is considering offers from investors in a bid to spin off
its drug research and development laboratory in Japan and make it
an independent entity, according to media reports.
Sanofi-Aventis hopes it can buck a pharma industry trend of
declining numbers of new drugs with potentially 31 new drug
submissions over the next 3 years.
Indian IT firm Tata Consultancy Services (TCS) has bagged its
second high profile pharma outsourcing deal this year with a new
multi-year contract with Swiss drug maker Roche.
The end of the tunnel seems to be getting closer for South
African manufacturer Enaleni as the firm confirmed it will resume
production in its recently closed Durban facility in the next ten
days.
The often cited decline in R&D productivity and dwindling
innovation within the pharma industry is actually a thing of the
past, according to Wyeth's head of business development.
The pharmaceutical industry has come up top in the most
Intellectual Property (IP)-intensive industry in the US, according
to a report released this week.
Some of the world's largest pharma firms have set out what
therapeutic areas and specific mechanisms are becoming more
important to them, and which will be left by the wayside.
Pharmaceutical packaging and processing machinery specialist IMA
has announced its half year results, with its active expansion
plans paying dividends and its pharma business going strong.
Pfizer, among others, recently offered an insight into R&D
outsourcing in Japan, where this services market is still fairly
immature, with growth potential in several key areas.
Sanofi-Aventis' hotly touted anti-obesity blockbuster drug has
become weighted down in safety concerns as the French company
withdraws its New Drug Application (NDA) in the US and awaits a
safety review in the EU.
China's resolve to clean up corruption in its pharma industry has
intensified as the former assistant to the
already-condemned-to-death former drug chief has now been charged.
